ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
October 27 2021 - 7:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
today announced that it will host a conference call and live
webcast on Tuesday, November 2, 2021, at 8:30 a.m. EDT to report
financial results for the third quarter 2021 and provide business
updates.
To access the live call, please dial 833-303-1198 (domestic) or
+1 914-987-7415 (international) and provide conference ID 4035885.
A live webcast of the presentation will be available under “Events
and Presentations” in the Investors section of the ADC Therapeutics
website at ir.adctherapeutics.com. The archived webcast will be
available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland,
and has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211027005253/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com Tel.: +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com Tel.: +1 917 288 7023
EU Media Alexandre Müller Dynamics Group
amu@dynamicsgroup.ch Tel: +41 (0) 43 268 3231
USA Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com Tel.: +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Sep 2023 to Sep 2024